Therapy development updates
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Search results
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Disulfiram (Antabuse), FDA-approved for deterring alcohol, is in a phase 1 trial at the University of Washington to improve vision in retinitis pigmentosa.
Are you affected by inherited sight loss? We are here to help.
Age-related macular degeneration (ARMD or AMD) is the commonest cause of blindness in thewestern world.
As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.
X-linked inheritance means that the faulty gene is located on the X chromosome, the larger of the two sex chromosomes.
Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.
New Eye Care Support Pathway wins cross-sector backing for transforming the way people with care needs and sight loss are helped emotionally and practically.